Back to Search Start Over

Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes.

Authors :
Foussard, Ninon
Saulnier, Pierre-Jean
Potier, Louis
Ragot, Stéphanie
Schneider, Fabrice
Gand, Elise
Monlun, Marie
Baillet-Blanco, Laurence
Velho, Gilberto
Marre, Michel
Roussel, Ronan
Rigalleau, Vincent
Mohammedi, Kamel
Hadjadj, Samy
SURDIAGENE Study Group
Source :
Diabetes Care; Nov2020, Vol. 43 Issue 11, p2751-2759, 9p
Publication Year :
2020

Abstract

<bold>Objective: </bold>We evaluated the association between diabetic retinopathy stages and lower-extremity arterial disease (LEAD), its prognostic value, and the influence of potential contributors to this relationship in a prospective cohort of patients with type 2 diabetes.<bold>Research Design and Methods: </bold>Diabetic retinopathy was staged at baseline as absent, nonproliferative, or proliferative. A Cox regression model was fitted in order to compute the hazard ratio (HR) (95% CI) for major LEAD (lower-limb amputation or revascularization) during follow-up by baseline retinopathy stages. The retinopathy-LEAD association was assessed in subgroups by age, sex, diabetes duration, HbA1c, systolic blood pressure, diabetic kidney disease, smoking, and macrovascular disease at baseline. The performance of retinopathy in stratifying LEAD risk was assessed by using the C statistic, integrated discrimination improvement (IDI), and net reclassification improvement (NRI).<bold>Results: </bold>Among 1,320 participants without a history of LEAD at baseline, 94 (7.1%) developed a major LEAD during a 7.1-year median follow-up (incidence rate 9.6 per 1,000 person-years [95% CI 7.8-11.7]). The LEAD incidence rate (per 1,000 person-years) increased as retinopathy worsened: it was 5.5 (95% CI 3.9-7.8) in participants in whom retinopathy was absent, 14.6 (11.1-19.3) in those with nonproliferative retinopathy, and 20.1 (11.1-36.3) in those with proliferative retinopathy. Nonproliferative retinopathy (adjusted HR 2.31 [95% CI 1.43-3.81], P = 0.0006) and proliferative retinopathy (3.14 [1.40-6.15], P = 0.007) remained associated with major LEAD. No heterogeneity was observed across subgroups. Retinopathy enhanced the C statistic (+0.023 [95% CI 0.003-0.044], P = 0.02), IDI (0.209 [0.130-0.321], P < 0.001), and NRI (0.562 [0.382-0.799], P < 0.001) values for risk of LEAD, beyond traditional risk factors.<bold>Conclusions: </bold>An independent dose-response relationship was identified between diabetic retinopathy stages and major LEAD. Retinopathy yielded incremental prognostic information for stratifying risk of LEAD, suggesting its usefulness as a predictor of LEAD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01495992
Volume :
43
Issue :
11
Database :
Complementary Index
Journal :
Diabetes Care
Publication Type :
Academic Journal
Accession number :
146526405
Full Text :
https://doi.org/10.2337/dc20-1085